Search - tctmd.com

Displaying 281 - 300 of 330

Sort: Relevancy | Date

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

News Daily News

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Michael O'Riordan

June 26, 2017

Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line

News Conference News TVT 2017

Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line

Michael O'Riordan

June 20, 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

Michael O'Riordan

June 16, 2017

Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows

News Conference News TVT 2017

Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows

Michael O'Riordan

June 15, 2017

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

News Daily News

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Michael O'Riordan

June 06, 2017

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

News Daily News

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Michael O'Riordan

June 06, 2017

Embolic Protection During TAVR Reduces Volume of Cerebral Lesions, but Clinical Benefit Not Evident: Meta-analysis

News Conference News EuroPCR 2017

Embolic Protection During TAVR Reduces Volume of Cerebral Lesions, but Clinical Benefit Not Evident: Meta-analysis

Michael O'Riordan

May 26, 2017

EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure

News Conference News EuroPCR 2017

EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure

Michael O'Riordan

May 24, 2017

News Conference News EuroPCR 2017

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Michael O'Riordan

May 17, 2017

High-Volume Surgeons More Likely to Perform Durable Mitral Valve Repairs, Have Better Outcomes

News Daily News

High-Volume Surgeons More Likely to Perform Durable Mitral Valve Repairs, Have Better Outcomes

Michael O'Riordan

May 04, 2017

News Daily News

Boston Scientific Adds Two More TAVR Valves With Symetis Purchase

Michael O'Riordan

March 30, 2017

Simplified MRI Imaging Tests May Help ID Kids at High CV Risk During Sports

News Conference News ACC 2017

Simplified MRI Imaging Tests May Help ID Kids at High CV Risk During Sports

Michael O'Riordan

March 24, 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

Live From Washington: ACC 2017, Day Three

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

March 19, 2017

Live From Washington: ACC 2017, Day Two

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

March 18, 2017

Live From Washington: ACC 2017, Day One

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

March 17, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Amid Sluggish Trial Enrollment, Transcatheter Mitral Valve Field Asks: Just How Big Is the Unmet Need?

News Conference News CRT 2017

Amid Sluggish Trial Enrollment, Transcatheter Mitral Valve Field Asks: Just How Big Is the Unmet Need?

Michael O'Riordan

February 27, 2017

Boston Scientific Recalls All Lotus Valves, Including Lotus with Depth Guard

News Daily News

Boston Scientific Recalls All Lotus Valves, Including Lotus With Depth Guard

Michael O'Riordan

February 23, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.